Stocks · News reference
Barclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wedbush Raises Price Target on Janux Therapeutics to $40
Wedbush Securities increased its price target for Janux Therapeutics from $36 to $40 while maintaining an Outperform rating.
Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics reported its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical portfolio.
Janux Therapeutics Schedules Third Quarter 2026 Earnings Announcement
Janux Therapeutics, Inc. has scheduled the release of its financial results for the third quarter of 2026 for November 10, 2026.
Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011
Janux Therapeutics announced it will host a virtual event on November 9, 2026, to present initial clinical data from the Phase 1 single-ascending-dose study of JANX011 in healthy volunteers.
Janux Therapeutics Doses First Patient In The Phase 1 Clinical Trial For JANX013, Its PSMA-Targeted Tumor-Activated CD28 Co-Stimulatory Bispecific, In Patients With Metastatic Castration-Resistant Prostate Cancer
The program is initially being developed in combination with JANX007, with the goal of further enhancing the durability of anti-tumor immune responses through tumor-restricted CD28 co-stimulation. Over time, Janux